nonmammal

“But even if those succeed, introducing a protein like channelrhodopsin from a nonmammal species could set off a dangerous immune reaction in humans, warned Dr. Howard Federoff, a neuroscientist at Georgetown University and chairman of the National Institutes of Health committee that reviews all gene-therapy clinical trial protocols in the United States.”

The Beam that Flips the Switch for Autistism | Impact Lab